Tthe Regionalized Vaccine Manufacturing Collaborative launched its new strategy during the recent Global Pandemic Preparedness Summit 2024. “We’ve never had a better chance to advance vaccine equity and health security for all than now, and through our 2024-27 strategy we’re committed to working with all partners to create regional vaccine manufacturing as a core element to deliver this, said RVMC’s Managing Director Frederik Kristensen. RVMC, an initiative supported by CEPI, the World Economic Forum and The National Academies of Sciences, Engineering, and Medicine, is uniquely suited to provide stakeholders with the support they need, being the only organization fully dedicated to the vaccine regionalization agenda, and intentionally positioned between regions and between global and regional bodies. #GPPS2024 #RVMC https://lnkd.in/dZ85gG_s
CEPI (Coalition for Epidemic Preparedness Innovations)
Forskningstjenester
We want to stop future epidemics by developing new vaccines for a safer world.
Om oss
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net
- Nettsted
-
http://www.cepi.net
Ekstern lenke til CEPI (Coalition for Epidemic Preparedness Innovations)
- Bransje
- Forskningstjenester
- Bedriftsstørrelse
- 51–200 ansatte
- Hovedkontor
- Oslo
- Type
- Ideell organisasjon
- Grunnlagt
- 2017
- Spesialiteter
- Epidemic Preparedness, Vaccine Development, Vaccine, Health, Science
Beliggenheter
-
Primær
Skøyen Atrium, Askekroken 11
Oslo, 0277, NO
-
215 Euston Road
London, England, GB
-
1901 Pennsylvania Ave NW
Washington, District of Columbia 20006, US
Ansatte i CEPI (Coalition for Epidemic Preparedness Innovations)
Oppdateringer
-
That’s a wrap on the Global Pandemic Preparedness Summit 2024 👏 The two-day summit, co-hosted by Ministério da Saúde, FIOCRUZ - Fundação Oswaldo Cruz, and CEPI featured more than 20 sessions and 80 speakers, advancing critical conversations that will help better prepare the world for future pandemic threats. These conversations centred around efforts to ramp up regional manufacturing and enable equitable access to health tools and countermeasures in response to epidemic and pandemic threats within 100 days. As well as examining how climate change is heightening pandemic risk, recent developments with the Pandemic Agreement negotiations and more. During the closing remarks Fiocruz president, Mario Moreira, also announced the Rio Declaration, calling for greater collaboration between the Global North & Global South to overcome disparities in access to health tools & countermeasures in LMICs. More: bit.ly/3LHzHvU A huge thanks to all the organizing partners, FIND, Unitaid, International Pandemic Preparedness Secretariat, Pan American Health Organization, the WHO Hub, and World Health Organization, as well as to the speakers and guests, for contributing to such an energising programme. A final report integrating all the Summit proceedings and recommendations from #GPPS2024 will be published in the coming weeks – stay tuned! In the meantime, check out the end of Summit release to explore more key highlights, or check out #GPPS2024. https://lnkd.in/eKA_yPXT
Global Summit reinvigorates efforts to prepare for future pandemics | CEPI
cepi.net
-
CEPI (Coalition for Epidemic Preparedness Innovations) la ut dette på nytt
A segunda edição da Cúpula Global de Preparação para Pandemias (GPPS, na sigla em inglês) teve início hoje (29/7). O evento reúne, em dois dias, especialistas em P&D e fabricação, autoridades governamentais, representantes da sociedade civil e líderes da indústria e da comunidade global de saúde para encontrar, em conjunto, soluções para enfrentar futuros surtos e pandemias de forma mais rápida e equitativa para todos os países. A Cúpula é organizada pela Coalizão para Inovações em Preparação para Epidemias (CEPI (Coalition for Epidemic Preparedness Innovations), a Fiocruz e o Ministério da Saúde. Pela manhã, Bio-Manguinhos / Fiocruz se tornou o mais novo parceiro a se juntar à rede da Cepi de fabricantes de vacinas no Sul Global. A rede trabalha para apoiar respostas rápidas e equitativas a futuras ameaças de doenças infecciosas emergentes. A inclusão da Fiocruz impulsionará significativamente os esforços de produção de vacinas na região da América Latina e do Caribe, aumentando a capacidade para produzir imunizantes em resposta a ameaças epidêmicas e pandêmicas. A Coordenação de Comunicação Social da Fiocruz montou um espaço para discussões sobre os desafios na preparação para pandemias dos países do Sul Global. Diversos especialistas estão sendo entrevistados para uma série que estará no canal da Fundação. #fiocruz #gpps2024 #pandemias
-
-
-
-
-
3
-
-
Great to see these very promising results from a Phase 1 clinical trial of a vaccine candidate against Rift Valley Fever demonstrating a high safety profile and excellent tolerability, eliciting robust immune responses. This is an important step towards a safe and effective RVF vaccine for human use. The trial was conducted in Belgium by Wageningen Bioveterinary Research funded by CEPI with support form #Horizon2020 and is recently published in The Lancet. Rift Valley Fever is a potential deadly viral disease and has been a CEPI priority since 2019. It most commonly affects domesticated animals, such as cattle, sheep, goats, and camels. However, Rift Valley Fever can also cause infection and outbreaks in people, symptoms of which range from mild disease to a severe haemorrhagic form that can have up to 50% fatality. Read more about Rift Valley Fever on our website 👇 https://lnkd.in/dhbF_swg
💉🚶♂️ The live-attenuated Rift Valley fever vaccine called ‘hRVFV-4s’ was shown safe in 75 participants in a Phase 1 clinical trial performed in Belgium. The outcomes of the trial were published in The Lancet Infectious Diseases. “We are pleased to see that the participants in this first human trial didn’t experience any major adverse events following vaccination and a promising immune response was induced”, says Paul Wichgers Schreur, researcher at Wageningen Bioveterinary Research and leading the LARISSA consortium that develops the vaccine. Rift Valley fever virus, a pathogen to ruminants, camelids, and humans, is an emerging mosquito-borne bunyavirus currently endemic to Africa and the Arabian Peninsula. Although animals are primarily infected via mosquito bites, humans mainly become infected following contact with infected tissues or fluids of infected animals. “There is an urgent need for adequate countermeasures, especially for humans, because effective therapeutics or vaccines are not yet available”, explains Paul. WBVR is the leading partner the LARISSA consortium that develops the live-attenuated hRVFV-4s vaccine beyond initial proof of concept. The consortium is funded by the CEPI (Coalition for Epidemic Preparedness Innovations) with support from the EU Horizon 2020 programme. In this first human trial The hRVFV-4s vaccine showed a favourable safety profile, good tolerability, and induced a strong humoral and cellular immune response in healthy individuals. Given these promising outcomes, further evaluation of the vaccine in populations at highest risk for Rift Valley fever is warranted. 👉 More information on this trial is available in the scientific paper published in The Lancet Infectious Diseases: https://lnkd.in/egebfKkQ #OneHealth #research #vaccinedevelopment
-
-
Day 1 of the Global Pandemic Preparedness Summit 2024 is complete. Thank you to all our speakers and guests today who contributed to these vital discussions. Lots of fascinating exchanges today looking at: 🔵 Opportunities to strengthen disease surveillance 🔵 How close we are to realizing the #100DaysMission 🔵 Enabling equitable access through regional production 🔵 How we can prepare for a zoonotic flu pandemic And plenty more. One clear theme has emerged: we’ve made significant progress in pandemic readiness and preparedness, but there is a long way to go before the world can confidently respond quickly and equitably to a pandemic threat. #GPPS2024 is a key forum for raising these issues and having discussions that can carve a clear path forward, helping to reinvigorate momentum behind global pandemic preparedness so that we can take the threat of pandemics off the table once and for all. Join us tomorrow for Day 2 of #GPPS2024. You can listen to panel sessions in real time by joining the live-stream link: bit.ly/3SaGm5r
-
-
A new clinical trial due to launch in the Democratic Republic of Congo and other countries in Africa will assess whether an mpox vaccine can protect people against the disease after they have come into contact with the potentially deadly infection: https://lnkd.in/dsCNkREY Funded by CEPI and the Canadian Institutes of Health Research | Instituts de recherche en santé du Canada, the ‘SMART’ trial aims to find out if post-exposure vaccination of Bavarian Nordic’s MVA-BN® mpox vaccine could reduce the risk of secondary mpox cases, or, if a person contracts mpox, could reduce their severity of illness. As H.E. Dr Jean Kaseya, Director General of Africa CDC, shared: “The SMART trial demonstrates the power of scientific collaboration, which could provide important data on the potential role of post-exposure mpox vaccinations.” Evidence generated could be crucial in shaping mpox vaccination strategies to help tackle the escalating outbreak of mpox in the DRC and neighbouring countries. Over 11,000 cases and 443 deaths have been reported in the DRC so far this year, with children accounting for the majority of infections and deaths. The announcement was made today at the launch of the Global Pandemic Preparedness Summit 2024, co-hosted by CEPI, Ministério da Saúde and FIOCRUZ - Fundação Oswaldo Cruz in Rio de Janeiro, Brazil: cepi.net/gpps
New clinical trial will assess if mpox vaccination works after virus exposure | CEPI
cepi.net
-
📣 We are delighted to announce that Brazil’s Bio-Manguinhos / Fiocruz, one of the largest vaccine manufacturers in Latin America, has joined CEPI’s network of vaccine manufacturers in the Global South, working to support faster and more equitable responses to future emerging infectious disease threats. The partnership was announced today at the Global Pandemic Preparedness Summit 2024, a unique meeting co-hosted by CEPI, FIOCRUZ - Fundação Oswaldo Cruz, and Ministério da Saúde to reinvigorate momentum behind the pandemic preparedness and response agenda. CEPI will support Bio-Manguinhos/Fiocruz to significantly boost and expand its local vaccine production efforts in the Latin American and Caribbean region to make vaccines faster and more accessible in response to future epidemic and pandemic threats. Regionalised vaccine manufacturing could help contain novel outbreaks in as little as 100 days, giving the world a fighting chance of defusing a pandemic before it starts. This could save millions of lives and prevent a socioeconomic crisis as seen during COVID-19. More about our partnership: https://lnkd.in/eqMUnwu8 Livestream the Global Pandemic Preparedness Summit #GPPS2024 over the next two days, with expert sessions delving into regionalised manufacturing approaches: Day 1, Mon 29 Jul: http://bit.ly/4cE4khJ; Day 2, Tues 30 Jul: http://bit.ly/3SaGm5r
Mobilising Brazil’s manufacturing might to support vaccine production in the Global South | CEPI
cepi.net
-
The Global Pandemic Preparedness Summit 2024, co-hosted by Ministério da Saúde, FIOCRUZ - Fundação Oswaldo Cruz and CEPI begins tomorrow! The two-day Summit will be a vital chance to reinvigorate momentum for global pandemic preparedness, driving forward important conversations that will help the world respond faster and more equitably to future outbreaks. Check out the full programme and array of expert speakers here: cepi.net/gpps Did you know you can join all #GPPS2024 panel sessions by joining the live-stream links (active on the day): 🔵 Day 1, Mon 29 July: bit.ly/4cE4khJ 🔵 Day 2, Tues 30 July: bit.ly/3SaGm5r
-
In an outbreak, every day counts. Removing duplicative efforts and streamlining processes could greatly impact how quickly organizations can respond to emerging outbreaks. CEPI, whose primary focus is vaccine development, and ISARIC - International Severe Acute Respiratory and Emerging Infection Consortium, whose primary focus is therapeutics development, have begun a trial of such a collaboration – complementing each other’s R&D needs to accelerate the development of available defences against viral outbreaks. Find out more about this collaboration: https://lnkd.in/e3znZYky
From silo to synergy: working together to accelerate defences against viral outbreaks | CEPI
cepi.net
-
A warm welcome from everyone at CEPI to Aurélia Nguyen, CEPI's new Deputy CEO.
I am delighted to announce that global health expert Aurélia Nguyen will be joining CEPI (Coalition for Epidemic Preparedness Innovations) on October 1, 2024, as our new Deputy CEO: https://lnkd.in/dtcxZFQr Aurélia has always been an incredible partner to CEPI and has an impressive track record both in leading teams and in delivering ambitious plans to improve access to vaccines. She brings both a wealth of experience from her career in the multilateral and private sectors and fresh thinking to what is going to be a critical role at CEPI. Aurélia joins CEPI from Gavi, the Vaccine Alliance – where she held roles including Chief Programme Officer and Managing Director of the Covax Facility. Aurélia has a proven track record in driving the design of vaccine programs and delivery of new vaccines as well as extensive leadership experience with a particular focus on gender and diversity. Aurélia succeeds Dr Frederik Kristensen who became Managing Director of the Regionalized Vaccine Manufacturing Collaborative (RVMC) in January 2024.
CEPI appoints Aurélia Nguyen as Deputy CEO | CEPI
cepi.net